001     131068
005     20240228145602.0
024 7 _ |a 10.1038/nature24294
|2 doi
024 7 _ |a pmid:29144447
|2 pmid
024 7 _ |a 0028-0836
|2 ISSN
024 7 _ |a 1476-4687
|2 ISSN
024 7 _ |a altmetric:28617718
|2 altmetric
037 _ _ |a DKFZ-2017-06135
041 _ _ |a eng
082 _ _ |a 070
100 1 _ |a Raffel, Simon
|0 P:(DE-He78)15e7a0fdb8cf2ea0ac289bcde71a2024
|b 0
|e First author
245 _ _ |a BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.
260 _ _ |a London [u.a.]
|c 2017
|b Nature Publ. Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1525782369_9511
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The branched-chain amino acid (BCAA) pathway and high levels of BCAA transaminase 1 (BCAT1) have recently been associated with aggressiveness in several cancer entities. However, the mechanistic role of BCAT1 in this process remains largely uncertain. Here, by performing high-resolution proteomic analysis of human acute myeloid leukaemia (AML) stem-cell and non-stem-cell populations, we find the BCAA pathway enriched and BCAT1 protein and transcripts overexpressed in leukaemia stem cells. We show that BCAT1, which transfers α-amino groups from BCAAs to α-ketoglutarate (αKG), is a critical regulator of intracellular αKG homeostasis. Further to its role in the tricarboxylic acid cycle, αKG is an essential cofactor for αKG-dependent dioxygenases such as Egl-9 family hypoxia inducible factor 1 (EGLN1) and the ten-eleven translocation (TET) family of DNA demethylases. Knockdown of BCAT1 in leukaemia cells caused accumulation of αKG, leading to EGLN1-mediated HIF1α protein degradation. This resulted in a growth and survival defect and abrogated leukaemia-initiating potential. By contrast, overexpression of BCAT1 in leukaemia cells decreased intracellular αKG levels and caused DNA hypermethylation through altered TET activity. AML with high levels of BCAT1 (BCAT1high) displayed a DNA hypermethylation phenotype similar to cases carrying a mutant isocitrate dehydrogenase (IDHmut), in which TET2 is inhibited by the oncometabolite 2-hydroxyglutarate. High levels of BCAT1 strongly correlate with shorter overall survival in IDHWTTET2WT, but not IDHmut or TET2mut AML. Gene sets characteristic for IDHmut AML were enriched in samples from patients with an IDHWTTET2WTBCAT1high status. BCAT1high AML showed robust enrichment for leukaemia stem-cell signatures, and paired sample analysis showed a significant increase in BCAT1 levels upon disease relapse. In summary, by limiting intracellular αKG, BCAT1 links BCAA catabolism to HIF1α stability and regulation of the epigenomic landscape, mimicking the effects of IDH mutations. Our results suggest the BCAA-BCAT1-αKG pathway as a therapeutic target to compromise leukaemia stem-cell function in patients with IDHWTTET2WT AML.
536 _ _ |a 311 - Signalling pathways, cell and tumor biology (POF3-311)
|0 G:(DE-HGF)POF3-311
|c POF3-311
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Falcone, Mattia
|0 P:(DE-He78)f299a5e8496e504b45347aa785206e36
|b 1
700 1 _ |a Kneisel, Niclas
|0 P:(DE-He78)0a651ad67f9c5fc48da2c1296b2644d7
|b 2
700 1 _ |a Hansson, Jenny
|b 3
700 1 _ |a Wang, Wei
|0 P:(DE-He78)e19f7f8051b12f0faf7b251ef382263f
|b 4
700 1 _ |a Lutz, Christoph
|b 5
700 1 _ |a Bullinger, Lars
|b 6
700 1 _ |a Poschet, Gernot
|b 7
700 1 _ |a Nonnenmacher, Yannic
|b 8
700 1 _ |a Barnert, Andrea
|0 P:(DE-He78)bfc89a1754a6bf5f824dae9389ee9288
|b 9
|u dkfz
700 1 _ |a Bahr, Carsten
|0 P:(DE-He78)57a8e60704700d5fa3def0243b99b461
|b 10
|u dkfz
700 1 _ |a Zeisberger, Petra
|0 P:(DE-He78)a2e11989a461bebbb1ab7659e10c8d89
|b 11
|u dkfz
700 1 _ |a Przybylla, Adriana
|0 P:(DE-He78)a04326e65ca276a4b54d5fd127d9845f
|b 12
|u dkfz
700 1 _ |a Sohn, Markus
|0 P:(DE-He78)39965117aef10b17055de724893accee
|b 13
|u dkfz
700 1 _ |a Tönjes, Martje
|b 14
700 1 _ |a Erez, Ayelet
|b 15
700 1 _ |a Adler, Lital
|b 16
700 1 _ |a Jensen, Patrizia
|0 P:(DE-He78)fd0996cc352f39d48cda87f474b1d033
|b 17
700 1 _ |a Scholl, Claudia
|0 P:(DE-He78)2c1a21d1cf5fdc9e297512c9d1354250
|b 18
700 1 _ |a Fröhling, Stefan
|0 P:(DE-He78)f0144d171d26dbedb67c9db1df35629d
|b 19
700 1 _ |a Cocciardi, Sibylle
|b 20
700 1 _ |a Wuchter, Patrick
|b 21
700 1 _ |a Thiede, Christian
|b 22
700 1 _ |a Flörcken, Anne
|b 23
700 1 _ |a Westermann, Jörg
|b 24
700 1 _ |a Ehninger, Gerhard
|b 25
700 1 _ |a Lichter, Peter
|0 P:(DE-He78)e13b4363c5fe858044ef8a39c02c870c
|b 26
700 1 _ |a Hiller, Karsten
|b 27
700 1 _ |a Hell, Rüdiger
|b 28
700 1 _ |a Herrmann, Carl
|0 P:(DE-He78)be4a5aeed7282c071b3ff43e9685c48c
|b 29
|u dkfz
700 1 _ |a Ho, Anthony D
|b 30
700 1 _ |a Krijgsveld, Jeroen
|0 P:(DE-He78)939d5891259c638c1ab053b1456a578c
|b 31
700 1 _ |a Radlwimmer, Bernhard
|0 P:(DE-He78)d1939d434dd885fad08106329e3db719
|b 32
700 1 _ |a Trumpp, Andreas
|0 P:(DE-He78)732f4fbcddb0042251aa759a2e74d3b2
|b 33
|e Last author
773 _ _ |a 10.1038/nature24294
|g Vol. 551, no. 7680, p. 384 - 388
|0 PERI:(DE-600)1413423-8
|n 7680
|p 384 - 388
|t Nature
|v 551
|y 2017
|x 1476-4687
909 C O |o oai:inrepo02.dkfz.de:131068
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)15e7a0fdb8cf2ea0ac289bcde71a2024
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)f299a5e8496e504b45347aa785206e36
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)0a651ad67f9c5fc48da2c1296b2644d7
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)e19f7f8051b12f0faf7b251ef382263f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)bfc89a1754a6bf5f824dae9389ee9288
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)57a8e60704700d5fa3def0243b99b461
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)a2e11989a461bebbb1ab7659e10c8d89
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)a04326e65ca276a4b54d5fd127d9845f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)39965117aef10b17055de724893accee
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 17
|6 P:(DE-He78)fd0996cc352f39d48cda87f474b1d033
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 18
|6 P:(DE-He78)2c1a21d1cf5fdc9e297512c9d1354250
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 19
|6 P:(DE-He78)f0144d171d26dbedb67c9db1df35629d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 26
|6 P:(DE-He78)e13b4363c5fe858044ef8a39c02c870c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 29
|6 P:(DE-He78)be4a5aeed7282c071b3ff43e9685c48c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 31
|6 P:(DE-He78)939d5891259c638c1ab053b1456a578c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 32
|6 P:(DE-He78)d1939d434dd885fad08106329e3db719
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 33
|6 P:(DE-He78)732f4fbcddb0042251aa759a2e74d3b2
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-311
|2 G:(DE-HGF)POF3-300
|v Signalling pathways, cell and tumor biology
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2017
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NATURE : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1060
|2 StatID
|b Current Contents - Agriculture, Biology and Environmental Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 30
|0 StatID:(DE-HGF)9930
|2 StatID
|b NATURE : 2015
920 1 _ |0 I:(DE-He78)G102-20160331
|k G102
|l Angewandte Funktionelle Genomik
|x 0
920 1 _ |0 I:(DE-He78)A010-20160331
|k A010
|l Stammzellen und Krebs
|x 1
920 1 _ |0 I:(DE-He78)B060-20160331
|k B060
|l Molekulare Genetik
|x 2
920 1 _ |0 I:(DE-He78)B230-20160331
|k B230
|l Proteomik
|x 3
920 1 _ |0 I:(DE-He78)B080-20160331
|k B080
|l Theoretische Bioinformatik
|x 4
920 1 _ |0 I:(DE-He78)G100-20160331
|k G100
|l Translationale Onkologie
|x 5
920 1 _ |0 I:(DE-He78)V960-20160331
|k V960
|l HI-Stem
|x 6
920 1 _ |0 I:(DE-He78)A060-20160331
|k A060
|l Mechanismen biomolekularer Wechselwirkungen
|x 7
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 8
920 1 _ |0 I:(DE-He78)L301-20160331
|k L301
|l DKTK Dresden
|x 9
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)G102-20160331
980 _ _ |a I:(DE-He78)A010-20160331
980 _ _ |a I:(DE-He78)B060-20160331
980 _ _ |a I:(DE-He78)B230-20160331
980 _ _ |a I:(DE-He78)B080-20160331
980 _ _ |a I:(DE-He78)G100-20160331
980 _ _ |a I:(DE-He78)V960-20160331
980 _ _ |a I:(DE-He78)A060-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a I:(DE-He78)L301-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21